drugset / Trial / NCT04434196
A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NaSequentialOpen-labelTreatment
Summary
CC-99282-CLL-001 study is a Phase IB dose escalation and expansion clinical study of CC-99282 administered in combination with Obinutuzumab in subjects with relapsed or refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Timeline
- Start
- 2020-12-21
- Primary completion
- 2024-05-21
- Completion
- 2024-05-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Golcadomide | Other / unclassified | — | Oral |
| Background | Obinutuzumab | Monoclonal antibody | 1000 mg | Intravenous |